AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
nabumetone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| cannabinoid receptors agonists | 1863 | 42924-53-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (COX2) inhibitor that is used in the management of pain associated with OSTEOARTHRITIS and RHEUMATOID ARTHRITIS.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 1 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 0.01 mg/mL | Bocci G, Oprea TI, Benet LZ |
| EoM (Fraction excreted unchanged in urine) | 0 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 125.15 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 35 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK2,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MET,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CG,PIM2,PRKDC,SIK3,STK33,TEK,TTK | 37 | |||
| kinase-selectivity-class | AXL,BRAF,EIF2AK3,GRK2,MAP2K6,MAPK12,PDK4 | 7 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 24, 1991 | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug hypersensitivity | 91.24 | 14.21 | 156 | 8073 | 463453 | 90156765 |
| Retinopathy | 31.79 | 14.21 | 12 | 8217 | 3522 | 90616696 |
| Periarticular disorder | 29.46 | 14.21 | 5 | 8224 | 51 | 90620167 |
| Rubella | 29.45 | 14.21 | 6 | 8223 | 174 | 90620044 |
| Completed suicide | 28.63 | 14.21 | 49 | 8180 | 145009 | 90475209 |
| Product dose omission issue | 26.62 | 14.21 | 72 | 8157 | 291615 | 90328603 |
| Injection site pain | 23.53 | 14.21 | 50 | 8179 | 173649 | 90446569 |
| Systemic lupus erythematosus | 22.73 | 14.21 | 3 | 8226 | 361893 | 90258325 |
| Maternal exposure during pregnancy | 22.58 | 14.21 | 3 | 8226 | 360060 | 90260158 |
| Glossodynia | 19.43 | 14.21 | 3 | 8226 | 321776 | 90298442 |
| Urinary tract infection | 19.02 | 14.21 | 66 | 8163 | 305566 | 90314652 |
| Wound | 17.90 | 14.21 | 3 | 8226 | 302977 | 90317241 |
| Limb mass | 14.91 | 14.21 | 7 | 8222 | 3521 | 90616697 |
| Off label use | 14.85 | 14.21 | 51 | 8178 | 1102201 | 89518017 |
| Depression | 14.62 | 14.21 | 60 | 8169 | 300541 | 90319677 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Splenic embolism | 51.65 | 20.49 | 10 | 2997 | 289 | 42618039 |
| Sideroblastic anaemia | 49.61 | 20.49 | 10 | 2997 | 357 | 42617971 |
| Vitamin B1 decreased | 49.08 | 20.49 | 10 | 2997 | 377 | 42617951 |
| Diaphragmatic injury | 45.83 | 20.49 | 8 | 2999 | 128 | 42618200 |
| Psoriatic arthropathy | 43.17 | 20.49 | 25 | 2982 | 24942 | 42593386 |
| Implant site infection | 38.15 | 20.49 | 10 | 2997 | 1151 | 42617177 |
| Marrow hyperplasia | 37.12 | 20.49 | 10 | 2997 | 1277 | 42617051 |
| Autoimmune haemolytic anaemia | 36.20 | 20.49 | 14 | 2993 | 5657 | 42612671 |
| Granulomatous liver disease | 32.73 | 20.49 | 8 | 2999 | 695 | 42617633 |
| Lentigo | 31.37 | 20.49 | 8 | 2999 | 826 | 42617502 |
| Mycobacterial infection | 29.93 | 20.49 | 10 | 2997 | 2658 | 42615670 |
| Granuloma | 29.49 | 20.49 | 11 | 2996 | 4030 | 42614298 |
| Psoriasis | 28.17 | 20.49 | 25 | 2982 | 48579 | 42569749 |
| Renal atrophy | 27.81 | 20.49 | 8 | 2999 | 1299 | 42617029 |
| Pulmonary granuloma | 25.84 | 20.49 | 8 | 2999 | 1669 | 42616659 |
| Ankylosing spondylitis | 23.57 | 20.49 | 11 | 2996 | 7045 | 42611283 |
| Splenic infarction | 22.92 | 20.49 | 8 | 2999 | 2423 | 42615905 |
| Pain | 22.78 | 20.49 | 52 | 2955 | 244796 | 42373532 |
| Upper gastrointestinal haemorrhage | 22.53 | 20.49 | 18 | 2989 | 30281 | 42588047 |
| Pulseless electrical activity | 21.70 | 20.49 | 11 | 2996 | 8426 | 42609902 |
| Melanocytic naevus | 21.30 | 20.49 | 8 | 2999 | 2984 | 42615344 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug hypersensitivity | 86.33 | 14.75 | 138 | 8437 | 453952 | 110126772 |
| Splenic embolism | 53.49 | 14.75 | 10 | 8565 | 216 | 110580508 |
| Sideroblastic anaemia | 46.64 | 14.75 | 10 | 8565 | 439 | 110580285 |
| Diaphragmatic injury | 45.07 | 14.75 | 8 | 8567 | 128 | 110580596 |
| Completed suicide | 41.00 | 14.75 | 70 | 8505 | 242311 | 110338413 |
| Vitamin B1 decreased | 39.30 | 14.75 | 10 | 8565 | 929 | 110579795 |
| Retinopathy | 34.59 | 14.75 | 13 | 8562 | 4416 | 110576308 |
| Marrow hyperplasia | 32.89 | 14.75 | 10 | 8565 | 1786 | 110578938 |
| Implant site infection | 31.33 | 14.75 | 10 | 8565 | 2093 | 110578631 |
| Rubella | 30.43 | 14.75 | 6 | 8569 | 173 | 110580551 |
| Autoimmune haemolytic anaemia | 29.44 | 14.75 | 15 | 8560 | 10552 | 110570172 |
| Injection site pain | 25.71 | 14.75 | 48 | 8527 | 177874 | 110402850 |
| Granulomatous liver disease | 25.54 | 14.75 | 8 | 8567 | 1576 | 110579148 |
| Mycobacterial infection | 24.09 | 14.75 | 10 | 8565 | 4407 | 110576317 |
| Off label use | 22.70 | 14.75 | 52 | 8523 | 1500133 | 109080591 |
| Renal atrophy | 22.46 | 14.75 | 8 | 8567 | 2338 | 110578386 |
| Product dose omission issue | 22.28 | 14.75 | 65 | 8510 | 321717 | 110259007 |
| Pain | 22.20 | 14.75 | 138 | 8437 | 954817 | 109625907 |
| Pulmonary granuloma | 21.77 | 14.75 | 8 | 8567 | 2553 | 110578171 |
| Granuloma | 19.49 | 14.75 | 11 | 8564 | 9479 | 110571245 |
| Psoriasis | 18.05 | 14.75 | 36 | 8539 | 139957 | 110440767 |
| Splenic infarction | 17.63 | 14.75 | 8 | 8567 | 4366 | 110576358 |
| Ankylosing spondylitis | 16.74 | 14.75 | 12 | 8563 | 15600 | 110565124 |
| Upper gastrointestinal haemorrhage | 16.68 | 14.75 | 20 | 8555 | 50076 | 110530648 |
| Surgery | 16.30 | 14.75 | 18 | 8557 | 41265 | 110539459 |
| Splenomegaly | 15.87 | 14.75 | 14 | 8561 | 24484 | 110556240 |
| Respiratory arrest | 15.79 | 14.75 | 21 | 8554 | 58278 | 110522446 |
| Febrile neutropenia | 15.28 | 14.75 | 3 | 8572 | 316764 | 110263960 |
| Limb mass | 15.18 | 14.75 | 7 | 8568 | 3962 | 110576762 |
| Emotional distress | 15.08 | 14.75 | 18 | 8557 | 44829 | 110535895 |
| Nail infection | 14.82 | 14.75 | 6 | 8569 | 2482 | 110578242 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | M01AX01 | MUSCULO-SKELETAL SYSTEM ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS Other antiinflammatory and antirheumatic agents, non-steroids |
| FDA CS | M0001335 | Anti-Inflammatory Agents, Non-Steroidal |
| FDA MoA | N0000000160 | Cyclooxygenase Inhibitors |
| MeSH PA | D000700 | Analgesics |
| MeSH PA | D000893 | Anti-Inflammatory Agents |
| MeSH PA | D000894 | Anti-Inflammatory Agents, Non-Steroidal |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D016861 | Cyclooxygenase Inhibitors |
| MeSH PA | D018501 | Antirheumatic Agents |
| MeSH PA | D018689 | Sensory System Agents |
| MeSH PA | D018712 | Analgesics, Non-Narcotic |
| MeSH PA | D052246 | Cyclooxygenase 2 Inhibitors |
| FDA EPC | N0000175722 | Nonsteroidal Anti-inflammatory Drug |
| CHEBI has role | CHEBI:35475 | non-steroidal anti-inflammatory drug |
| CHEBI has role | CHEBI:35481 | non-narcotic analgesic |
| CHEBI has role | CHEBI:35842 | antirheumatic drug |
| CHEBI has role | CHEBI:50266 | prodrug |
| CHEBI has role | CHEBI:50629 | cyclooxygenase 2 inhibitor |
Related Drugs by ATC class:
M01AX Other antiinflammatory and antirheumatic agents, non-steroids 13 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Rheumatoid arthritis | indication | 69896004 | DOID:7148 |
| Osteoarthritis | indication | 396275006 | |
| Ankylosing spondylitis | off-label use | 9631008 | DOID:7147 |
| Juvenile rheumatoid arthritis | off-label use | 410795001 | |
| Alcoholism | contraindication | 7200002 | |
| Peptic ulcer | contraindication | 13200003 | DOID:750 |
| Acute gastric ulcer with perforation | contraindication | 19850005 | |
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Gastrointestinal ulcer | contraindication | 40845000 | |
| Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
| Acute nephropathy | contraindication | 58574008 | |
| Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
| Gastrointestinal hemorrhage | contraindication | 74474003 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Coronary artery bypass graft | contraindication | 232717009 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Pregnancy, function | contraindication | 289908002 | |
| Cardiovascular event risk | contraindication | 395112001 | |
| Smokes tobacco daily | contraindication | 449868002 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Prostaglandin G/H synthase 2 | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
| Prostaglandin G/H synthase 1 | Enzyme | IC50 | 3.34 | WOMBAT-PK | |||||
| Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.73 | DRUG MATRIX | |||||
| Cytochrome P450 1A2 | Enzyme | IC50 | 5.30 | DRUG MATRIX | |||||
| Amine oxidase [flavin-containing] A | Enzyme | IC50 | 6.00 | DRUG MATRIX |
External reference:
| ID | Source |
|---|---|
| 4020284 | VUID |
| N0000148161 | NUI |
| D00425 | KEGG_DRUG |
| 4020284 | VANDF |
| C0068334 | UMLSCUI |
| CHEBI:7443 | CHEBI |
| NBO | PDB_CHEM_ID |
| CHEMBL1070 | ChEMBL_ID |
| DB00461 | DRUGBANK_ID |
| D000077430 | MESH_DESCRIPTOR_UI |
| 4409 | PUBCHEM_CID |
| 7245 | IUPHAR_LIGAND_ID |
| 4855 | INN_ID |
| LW0TIW155Z | UNII |
| 31448 | RXNORM |
| 41877 | MMSL |
| 5142 | MMSL |
| d00310 | MMSL |
| 003622 | NDDF |
| 108508000 | SNOMEDCT_US |
| 386859000 | SNOMEDCT_US |
| LW0TIW155Z | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Nabumetone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1657 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 28 sections |
| Nabumetone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1658 | TABLET, FILM COATED | 750 mg | ORAL | ANDA | 28 sections |
| Nabumetone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0440-5843 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 26 sections |
| Nabumetone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0440-5844 | TABLET, FILM COATED | 750 mg | ORAL | ANDA | 26 sections |
| Nabumetone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-3670 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 26 sections |
| Nabumetone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-3671 | TABLET, FILM COATED | 750 mg | ORAL | ANDA | 26 sections |
| Nabumetone 500 mg | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0722-7076 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 28 sections |
| Nabumetone 750 mg | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0722-7077 | TABLET, FILM COATED | 750 mg | ORAL | ANDA | 28 sections |
| Nabumetone 1000 mg | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0722-7078 | TABLET, FILM COATED | 1000 mg | ORAL | ANDA | 28 sections |
| Nabumetone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-003 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 29 sections |
| Nabumetone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-120 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 28 sections |
| Nabumetone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-271 | TABLET, FILM COATED | 750 mg | ORAL | ANDA | 29 sections |
| Nabumetone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-273 | TABLET | 500 mg | ORAL | ANDA | 25 sections |
| RELAFEN DS | HUMAN PRESCRIPTION DRUG LABEL | 1 | 15370-170 | TABLET | 1000 mg | ORAL | ANDA | 26 sections |
| NABUMETONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-160 | TABLET | 750 mg | ORAL | ANDA | 25 sections |
| Nabumetone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-230 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 29 sections |
| Nabumetone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-231 | TABLET, FILM COATED | 750 mg | ORAL | ANDA | 29 sections |
| Nabumetone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-077 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 28 sections |
| Nabumetone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-078 | TABLET, FILM COATED | 750 mg | ORAL | ANDA | 29 sections |
| Nabumetone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33358-251 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 29 sections |
| Nabumetone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33358-252 | TABLET, FILM COATED | 750 mg | ORAL | ANDA | 29 sections |
| NABUMETONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42549-523 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 23 sections |
| NABUMETONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42549-648 | TABLET, FILM COATED | 750 mg | ORAL | ANDA | 29 sections |
| Nabumetone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-972 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 24 sections |
| Nabumetone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45865-111 | TABLET | 750 mg | ORAL | ANDA | 22 sections |
| Nabumetone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45865-351 | TABLET, FILM COATED | 750 mg | ORAL | ANDA | 29 sections |
| Nabumetone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45865-464 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 29 sections |
| Nabumetone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45865-997 | TABLET, FILM COATED | 750 mg | ORAL | ANDA | 28 sections |
| Nabumetone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-0747 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 26 sections |
| Nabumetone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-0800 | TABLET, FILM COATED | 750 mg | ORAL | ANDA | 26 sections |